Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 974

NCT06948422

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Orforglipron (GZL1)n/rn/rn/rn/r
Orforglipron (GZL2)n/rn/rn/rn/r

Not shown

  • Orforglipron (GZL1): endpoint not reported
  • Orforglipron (GZL2): endpoint not reported